CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

CytomX Therapeutics, Inc.

Summit Therapeutics is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of medicinal therapies intended to improve quality of life and resolve serious unmet medical needs, self-described.

Summit Therapeutics

CytomX Therapeutics is a biopharmaceutical company that researches and develops therapies to combat cancer by using the disease's own mechanisms against itself.

CytomX Therapeutics

CytomX Therapeutics, Inc. is committed to changing the treatment of cancer with our novel Probody® therapeutic platform. We have a broad pipeline comprised of five clinical-stage programs, with even more in development. 

Our commitment to transforming lives with safer, more effective therapies is driven by our curiosity and passion for innovation, and our belief that by acting with integrity in an honest, respectful, ethical manner, we have the power to change lives. Our workplace embodies collaboration, open communication, celebrating our successes and holding each other to the highest possible standards. 

CytomX embraces diversity and seeks to enhance and maintain our culture of equity and inclusion which encourages individuals to be themselves, feel involved, respected and connected.

We at CytomX believe that we benefit from each other’s ideas and experiences. We accept our differences and learn from one another, improve together, and embrace change to achieve our corporate and individual objectives. This belief applies to how we work together at CytomX, how we work with others outside CytomX, how we represent CytomX in our communities, and how we endeavor to bring our scientific innovations to a diverse patient population.

CytomX acknowledges the importance of diversity, equity and inclusion initiatives and that they require an evolving and ongoing commitment. CytomX is an equal opportunity employer and does not discriminate against any individual or potential candidate because of race, color, religion, sex, national origin, sexual preference or any other legally protected category.

CytomX is located in South San Francisco, California, the birthplace of biotechnology. Learn more about us and how we are advancing science to treat cancer differently at www.cytomX.com.

Canaan Partners

Third Rock Ventures

Casdin Capital

Wellington Management

Perceptive Advisors

Redmile Group

Cormorant Asset Management

Deerfield

Tekla Capital Management

Venrock

Today we announced second quarter 2024 financial results, including progress related to our clinical-stage PROBODY® therapeutic programs. To learn more, read our press release and join our conference call and webcast at 5pm ET/2pm PT. https://lnkd.in/evS2MHHC

Happy National Intern Day! At CytomX, CREATIVITY is more than just a value—it's at the heart of everything we do. As we celebrate National Intern Day, we applaud our interns for embodying this core value, infusing their work in science with fresh perspectives and innovative thinking. They are the future of scientific discovery, paving the way for the next generation of leaders. Here's to the next generation of leaders shaping the future at CytomX!

Celebrating International Women's History Month at CytomX! As a culture that embraces diversity, we proudly honor the invaluable contributions of women in STEM. With over half of our organization being women, we recognize their significant impact and dedication. At CytomX, one of our values is COMMITMENT, and we are dedicated to our patients, teammates, and fostering a diverse and inclusive environment where everyone thrives. Here's to the inspiring women shaping the future of science and making significant impacts every day!

Happy Lunar New Year! This year marks the beginning of the Wood Dragon, symbolizing creativity and adaptability. At CytomX, we embrace CREATIVITY as one of our core values, as we believe that curiosity and innovation have the power to change lives! To celebrate, we hosted a special Lunar New Year Happy Hour, where we toasted the year ahead and honored the spirit of innovation that defines our work. Wishing everyone a prosperous and joyful year ahead! 🐲 🎊

At CytomX, our mission is to transform the lives of cancer patients with safer, more effective therapies through the development of novel conditionally activated biologics. Watch our CEO Sean McCarthy's recent conversation with
Precision AQ to learn more!

Today at 2pm ET, our chief executive officer and chairman Sean McCarthy will participate in a fireside chat at the H.C. Wainwright & Co., LLC 2nd Annual Immune Cell Engager Virtual Conference. Tune into the webcast to listen live or hear the replay: https://lnkd.in/e8FurEhJ

Metric
Company Name	CytomX Therapeutics, Inc.	Summit Therapeutics
Symbol	CTMX
MSH ID	COM:CYTOMX	COM:SUMMITTHERAPEUTICS
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	US
Stage	Post-IPO Equity	Post-IPO Equity
Employee Count	120
Website	cytomx.com	summittherapeutics.com
LinkedIn	cytomx-therapeutics
Founders

Metric
Market Cap	102.07M
Enterprise Value
Monthly Web Traffic	5.32K	1.36K
Web Traffic Growth	-0.10	-0.08
Valuation
Raised Capital	93.60M	235M

Metric
Revenue	101.21M
Revenue (LTM)
Revenue (NTM)
Gross Profit	99.04M
EBITDA	-4.31M
Operating Income	-6.48M
Net Income	-569K
EPS	-0.01
Diluted EPS	-0.01
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.98
Operating Profit Margin	0.09
EBITDA Margin	-0.04
Net Profit Margin	0.14
Return on Equity	-0.03
Return on Assets	0.09
Return on Capital Employed	0.35

COM:CYTOMX

CytomX Therapeutics

Last Close

0.87

22/11 21:00

Market Cap

102.07M

Beta: -

Volume Today

1.23K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-4.58
P/B Ratio	-2.29
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.43
EV Multiple	18.87

Metric
Days Sales Outstanding	11.69
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle	40.36
Cash Conversion Cycle	-70.11
Asset Turnover	0.75

Metric
Operating Cash Flow	-56.03M
Free Cash Flow	-56.88M
Cash Flow to Debt	-4.01
Operating Cash Flow/Sales	-0.55
Free Cash Flow Yield	-0.37

Metric
Cash & Equivalents	17.17M
Accounts Receivable	32.55M
Inventory
Goodwill	949K
Debt to Capitalization	-0.42
Debt to Assets	0.07
Current Ratio	1.37
Quick Ratio	1.16

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.11
R&D to Revenue	1.03
SG&A to Revenue	0.43